case_images: PMC3934673_01
case_images: PMC3934673_02
case_images: PMC3934673_03
case_images: PMC3934673_04
case_images: Status of the pulmonary metastases prior to the treatment with the sunitinib-based combination (a) and in December 2006 after a response to the treatment (b).
case_images: cro-0007-0052-g01.jpg
case_images: PMC3934673_05_cro-0007-0052-g01.jpg
case_images: F1
case_images: By December of 2006, six weeks after initiation of therapy, the lung lesion had disappeared, but the liver lesion remained stable (fig. 1b).
case_images: PMC3934673_05
case_images: Status of the pulmonary metastases prior to the treatment with the sunitinib-based combination (a) and in December 2006 after a response to the treatment (b).
case_images: cro-0007-0052-g01.jpg
case_images: PMC3934673_05_cro-0007-0052-g01.jpg
case_images: F1
case_images: By December of 2006, six weeks after initiation of therapy, the lung lesion had disappeared, but the liver lesion remained stable (fig. 1b).
case_images: a Positive IHC staining for TOPO1 expression. b Positive IHC staining for c-kit.
case_images: cro-0007-0052-g02.jpg
case_images: PMC3934673_05_cro-0007-0052-g02.jpg
case_images: F2
case_images: Ariz., USA, for more detailed analysis (Target Now tumor profiling). This specimen showed overexpression of TOPO1 (fig. 2a), suggesting sensitivity to irinotecan. As a result, he was started on cycles of irinotecan 125 mg/m2 per week x 4, followed by 2 weeks off. The Caris Target Now analysis of the July 2010 sacral biopsy specimen had also shown continued expression of c-kit (fig. 2b).
case_images: PMC3934673_06